Home>>Signaling Pathways>> Others>>Bencianol (ZY15051)

Bencianol (ZY15051)

Catalog No.GC31028

Bencianol (ZY15051) is a the semisynthetic flavinoid, with anti-spasmogenic activities.

Products are for research use only. Not for human use. We do not sell to patients.

Bencianol (ZY15051) Chemical Structure

Cas No.: 85443-48-7

Size Price Stock Qty
1mg
$92.00
In stock
5mg
$184.00
In stock
10mg
$313.00
In stock
20mg
$552.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bencianol is a the semisynthetic flavinoid, with anti-spasmogenic activities.

Bencianol causes a dose-related (1-100 μg/mL) reversal of contractions induced by 5-hydroxytryptamine, nor-adrenaline, angiotensin II, prostaglandin F2a, and U-46619 (a thromboxane-A2 mimetic). Bencianol is more effective against contractions induced by EC50 compared to maximal concentrations of each agent, and is least effective against the thromboxane-A2 mimetic, U-46619[1]. Bencianol (0.1-100 nM) produces cytoprotective effects against CCl4 induced cell injury on the above three parameters[2].

[1]. Whalley ET, et al. Anti-spasmogenic effects of bencianol (ZY15051) on human cerebral arteries in vitro. Cephalalgia. 1985 Dec;5(4):217-21. [2]. Maignan MF, et al. Cytoprotective effects of Bencianol on porcine vascular endothelial cells in vitro. J Submicrosc Cytol. 1986 Jan;18(1):47-51.

Reviews

Review for Bencianol (ZY15051)

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bencianol (ZY15051)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.